Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-08-11
1993-01-05
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 3, 530304, 530303, A61K 3726
Patent
active
051770580
ABSTRACT:
Pharmaceutical formulations for the treatment of diabetes mellitus are disclosed, wherein the pharmaceutical formulations contain at least one insulin derivative modified with a base in position B31 of the insulin B chain and having an isoelectric point between 5.8 and 8.5 and/or at least one of its physiologically tolerated salts in a pharmaceutically acceptable excipient and a relatively high zinc ion content in the range from above 1 .mu.g to about 200 .mu.g of zinc/IU. The preferred insulin derivative modified with a base for this pharmaceutical formulation is human insulin-B31-Arg-OH and human insulin-B31-Arg-B32-Arg-OH. The formulation is used for the treatment of diabetes mellitus; it has a particularly favorable action profile.
REFERENCES:
patent: 2143591 (1939-01-01), Scott et al.
patent: 2354211 (1944-07-01), Lang et al.
patent: 4608364 (1986-08-01), Grau
patent: 4652547 (1987-03-01), Chance et al.
patent: 4701440 (1987-10-01), Grau
Scott et al., "The Effect of Zinc Salt on the Action of Insulin," J. Pharmakol. 55 (1935) pp. 206-221.
Ekstrom Richard C.
Hoechst Aktiengesellschaft
Wax Robert A.
LandOfFree
Pharmaceutical formulation for the treatment of diabetes mellitu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulation for the treatment of diabetes mellitu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation for the treatment of diabetes mellitu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2390628